- In October 2022, Pfizer Completed Its Acquisition Of Global Blood Therapeutics, Inc. (Gbt), A Biopharmaceutical Company Focused On Developing Innovative Treatments For Underserved Patient Populations, Starting With Sickle Cell Disease (Scd). This Acquisition Enhances Pfizer's Portfolio In The Field Of Blood Disorders And Strengthens Its Commitment To Addressing Critical Unmet Medical Needs. The Acquisition Marks A Significant Step In Pfizer’s Strategy To Expand Its Presence In Rare Disease Treatments And Provide Transformative Therapies For Patients Worldwide
- In June 2022, Amgen Announced That Its Clinical Trials For Apremilast, Focused On Treating Pediatric Patients With Active Oral Ulcers Associated With Behçet’s Disease, Had Progressed To Phase 3. The Study Is Expected To Conclude By 2029, And Its Success Could Have A Significant Impact On Global Market Revenues. If Proven Effective, Apremilast Could Become A Key Treatment Option, Driving Both Market Growth And Improved Outcomes For Pediatric Patients With Behçet’s Disease
- In June 2022, Peking Union Medical College Hospital Announced That Its Clinical Studies Evaluating The Efficacy And Safety Of Adalimumab Combined With A Medium Dose Of Oral Glucocorticosteroids For Refractory Behçet's Uveitis Had Entered Phase 3. The Study Is Expected To Conclude By 2026, And Its Success Could Significantly Influence Global Market Revenues. If Proven Effective, This Combination Therapy Could Become A Critical Treatment Option, Potentially Expanding The Market For Behçet’s Disease Treatments And Improving Outcomes For Patients With Refractory Uveitis
- In December 2021, Gyroscope Therapeutics, A Uk-Based Company Specializing In Ocular Gene Therapy, Announced That It Had Entered Into A Binding Agreement With Novartis For The Acquisition Of Its Entire Outstanding Share Capital. This Acquisition Will Enhance Novartis’ Position In The Gene Therapy And Ocular Disease Treatment Market. The Move Aligns With Novartis' Strategy To Expand Its Innovative Portfolio And Strengthen Its Capabilities In Gene-Based Treatments For Eye Conditions
- In February 2020, The European Medicines Agency (Ema) Granted Marketing Authorization Application (Maa) Approval For Otezla To Treat Adult Patients With Oral Ulcers Associated With Behçet’s Syndrome Who Require Systemic Therapies. This Approval Marked A Significant Step In Expanding Treatment Options For Patients With This Condition. Otezla’s Approval Offers A New, Effective Therapy For Managing Symptoms Of Behçet’s Syndrome, Potentially Improving Patient Outcomes And Enhancing The Treatment Landscape In Europe
Frequently Asked Questions
The market is segmented based on Global Behçet’s Disease Treatment Market Segmentation, By Type (Neuro-Behcet, Ocular-Behcet, and Vasculo-Behcet), Treatment (Corticosteroids, Immunosuppressive Agents, Immunomodulators, Phosphodiesterase 4 (PDE4) Inhibitor, Interleukin-1β Blocker, and Others), Route of Administration (Oral, and Injectable), End Users (Hospitals, Homecare, Specialty Clinics, and Others) – Industry Trends and Forecast to 2031
.
The Global Behets Disease Treatment Market size was valued at USD 13.37 USD Billion in 2023.
The Global Behets Disease Treatment Market is projected to grow at a CAGR of 6.5% during the forecast period of 2024 to 2031.
The market report covers data from the U.S., Canada And Mexico In North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest Of Europe In Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest Of Asia-Pacific (Apac) In The Asia-Pacific (Apac), Saudi Arabia, U.A.E., South Africa, Egypt, Israel, Rest Of Middle East And Africa (Mea) As A Part Of Middle East And Africa (Mea), Brazil, Argentina And Rest Of South America As Part Of South America..
